UK-based Hekka Labs has launched a decentralised healthcare ecosystem for far more efficient health record management. The firm will concentrate on the Southeast Asia market, starting with India, where it will establish the largest chronic disease data management network.

Hekka has cemented initial partnerships with three Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which has recently agreed to provide a minimum of 1.5 million medical records in 2022.

A further agreement to provide up to 20 separate blood biomarkers together with COVID-19 data on 100,000 patients, will form the basis of an initial trial for its blockchain audit trail platform.

IMMUNIDEX, a healthcare solution provider offering tests and applications that are driven by proprietary AI that can identify early immune-related risks and is well placed to capture highly valuable data for the Hekka network. 

TELEMEDICINE INDIAN CO, a startup offering multi telemedicine services, multiple blood tests, and health screening including COVID-19 testing will form another integral part of data generation for the Hekka ecosystem. 

Hekka Labs has set out to become the leading chronic illness and immunology platform in India. Hekka's private and public blockchain network solution will generate a new trust in Indian healthcare data management and can open up significant opportunity for both the domestic and global collaboration. This will lead to new levels of ethical standards and excellence for the Indian healthcare market.